Healthcare AI & Digital Health — 2026年11月9日 週次レポート
Healthcare AI & Digital Healthのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The Democratic midterm blue wave is the single most consequential development of the week for healthcare's medium-term trajectory. New committee chairs with aggressive oversight agendas — Sanders at HELP, Wyden at Finance — will scrutinize Medicare Advantage, private equity, and drug pricing, while bipartisan action on AI governance and prior authorization reform is the most immediately achievable legislative path. The wave does not reverse H.R. 1's Medicaid cuts in the near term, but it fundame…
- •CMS's simultaneous finalization of steeper-than-proposed physician payment cuts and a $4.35 billion first-year reduction in 340B drug reimbursements — both landing in the same week as the midterm results — creates a compounding financial pressure on safety-net hospitals and independent physician practices that will define the operational environment for 2027. The RPM third-party vendor ban's two-year delay to 2029 provides temporary relief for digital health companies but does not resolve the un…
- •AI is crossing from adoption to infrastructure in healthcare. Athenahealth's MCP connection to Claude, Mayo Clinic Platform's EHR-embedded decision support, Epic's AI-assisted nursing inbox management, and Hippocratic AI's Polaris 6 Ultra model upgrade collectively represent AI becoming a native layer of clinical and patient engagement workflows — not a bolt-on feature. The restructurings at Abridge and Heidi signal that the ambient AI documentation market is entering a consolidation phase where…
- •The measles outbreak's escalation to multiple deaths across Wisconsin, New York, and Pennsylvania — with the CDC's official count lagging state-reported figures — represents a public health failure with direct implications for vaccine policy, federal-state health authority relationships, and the credibility of federal health leadership. The outbreak is now the worst in decades and is occurring in a political environment where the federal government's vaccine messaging has been inconsistent.
- •The CVS Health split and Siemens Healthineers' IVD carve-out as Olyrian Diagnostics both reflect a broader trend of large healthcare conglomerates unbundling to unlock shareholder value and respond to regulatory pressure on vertical integration. Neither move fully resolves the underlying conflicts of interest that regulators and legislators have targeted, but both signal that the era of unconstrained healthcare vertical integration is ending.
今回の要点（18件）
- 1.Democrats flipped seven Senate seats and 21 House seats in the November 3 midterms, installing new committee chairs including Bernie Sanders at HELP and Ron Wyden at Finance, with bipartisan action on AI, cybersecurity, and prior authorization expected to be most immediately achievable [3a].
- 2.CMS finalized the 2027 Physician Fee Schedule with a 2.31% conversion factor reduction for non-APM participants — steeper than the proposed 1.68% — and finalized the 2027 OPPS rule with a 340B drug reimbursement cut from ASP plus 6% to ASP minus 28%, reducing Original Medicare drug payments by $4.35 billion in year one [3b].
- 3.CVS Health announced it will split into two companies by the first half of 2028, separating CVS Pharmacy from a new CVS Health entity retaining Aetna, Caremark, Oak Street Health, and Signify Health [3c].
- 4.Athenahealth launched athenaPatient MCP, connecting patient health records to Anthropic's Claude via the Model Context Protocol, with plans to expand to other AI models [3d].
- 5.Mayo Clinic Platform launched an AI-enabled clinical decision support tool embedded in EHR workflows, covering more than 35 specialties and 22 clinical calculators, updated daily from peer-reviewed literature [3e].
- 6.Hinge Health posted $235 million in Q3 revenue, up 52% year-over-year, and raised its 2026 full-year revenue outlook to between $879 million and $881 million, reflecting 50% year-over-year growth at the midpoint [3f].
- 7.Hims & Hers struck a deal with Eli Lilly to offer Zepbound and Foundayo through its platform at self-pay prices starting at $149 per month for Foundayo and $299 per month for Zepbound [3g].
- 8.The FDA granted accelerated approval to a new treatment for head and neck squamous cell carcinoma on November 5, confirmed as J&J's Rybrevant Faspro based on a 42% overall response rate [5a].
- 9.Japan's PMDA posted Basic Principles for the Use of AI in Regulatory Activities (Early Consideration) on November 2, the first formal articulation of AI governance for Japanese regulatory processes [4].
- 10.The U.S. measles outbreak reached 4,852 confirmed cases as of October 29, with Wisconsin reporting its first infant measles-associated death since 1990 and New York reporting its first child death in 30 years [3h].
- 11.Samaritan Health Services officially joined MultiCare Health System on November 1, creating an 18-hospital, $7.5 billion nonprofit system with a $700 million, 10-year investment commitment [3i].
- 12.Rush University System for Health and Endeavor Health announced plans to merge into a 12-hospital nonprofit with nearly $11 billion in annual revenue, targeting an early 2027 close [3j].
- 13.LeanTaaS acquired LookDeep Health to integrate computer vision and ambient intelligence into its iQueue hospital operations platform, with deployments reporting more than a 70% reduction in fall rates [3k].
- 14.Abridge cut its workforce as part of an organization-wide realignment, and Heidi reduced its headcount by 18%, affecting approximately 108 staff, as both ambient AI companies restructure for efficiency [3l].
- 15.Siemens Healthineers initiated the carve-out of its in vitro diagnostics business as a standalone company under the name Olyrian Diagnostics [13].
- 16.A federal court blocked CMS's moratorium on new ACA broker registrations on November 5, with the District Court of Maryland granting a preliminary injunction [3m].
- 17.Midstream Health raised $20 million in Series A funding to expand its AI financial operations platform for health systems, which is on pace to reach $100 million in client savings by end of 2026 [3n].
- 18.The MHRA published its Patient and Public Involvement and Engagement Plan 2026-2030 on November 5 and opened a Phase 1 evaluation survey for Digital Mental Health Technologies [10].
市場動向
AI Integration Into EHR and Patient-Facing Platforms Deepens
This week's activity shows AI moving from administrative support into direct patient-record access and clinical decision support. Athenahealth launched athenaPatient MCP, connecting patient health records to Anthropic's Claude via the Model Context Protocol, allowing patients to query their own clinical data through a general-purpose AI assistant [3d]. Mayo Clinic Platform launched an AI-enabled clinical decision support tool embedded directly in EHR workflows, covering more than 35 specialties …
Digital Health Platform Companies Post Strong Growth, Expand Multi-Condition Strategies
Digital health companies with multi-condition platforms reported robust Q3 results, signaling that the sector is maturing beyond single-indication point solutions. Hinge Health posted $235 million in Q3 revenue, up 52% year-over-year, and raised its 2026 full-year revenue outlook to between $879 million and $881 million, reflecting 50% year-over-year growth at the midpoint; the company is expanding from MSK into migraine and gastrointestinal care [3f]. Omada Health reported $91 million in Q3 rev…
GLP-1 Distribution Ecosystem Consolidates Around Branded Partnerships
The GLP-1 market is consolidating around branded drug partnerships as compounded alternatives face regulatory pressure. Hims & Hers struck a deal with Eli Lilly to offer Zepbound (tirzepatide) and Foundayo (orforglipron) directly through its platform at self-pay prices starting at $149 per month for Foundayo and $299 per month for Zepbound, mirroring its earlier Novo Nordisk partnership [3g]. The company had previously posted losses of $92 million in Q1 and $86 million in Q2 as it exited compoun…
Healthcare M&A Wave Continues With Multi-Billion Dollar Consolidation
Provider consolidation accelerated further this week. Samaritan Health Services officially joined MultiCare Health System on November 1, creating an 18-hospital, $7.5 billion nonprofit system with a $700 million, 10-year investment commitment from MultiCare into Samaritan facilities [3i]. Rush University System for Health and Endeavor Health announced plans to merge into a 12-hospital nonprofit with nearly $11 billion in annual revenue, targeting an early 2027 close [3j]. CVS Health announced it…
Measles Outbreak Reaches Crisis Levels as Vaccine-Preventable Disease Deaths Mount
The U.S. measles outbreak intensified significantly this week. As of October 29, the CDC reported 4,852 confirmed cases nationally, far outpacing 2025's total of 2,289 [3h]. Wisconsin reported its first measles-associated infant death since 1990 on November 5, with 431 cases across 13 counties in 2026 [3h]. New York reported its first measles-associated child death in 30 years on November 3. Pennsylvania has confirmed five measles-associated deaths. The outbreak is occurring against a backdrop o…
競合動向
EHR Platforms Race to Become AI Orchestration Hubs
The competitive dynamic among EHR and health IT platforms is shifting from data storage to AI orchestration. Athenahealth's athenaPatient MCP uses the Model Context Protocol — described by the company as an industry norm for AI interoperability — to connect Claude directly with the athenaOne platform, with plans to expand to other AI models [Source: https://www.fiercehealthcare.com/ai-and-machine-learning/athenahealth-launches-tool-bring-patient-health-records-anthropics-claude (company announce…
Ambient AI Companies Restructure as Market Matures
The ambient AI clinical documentation sector is undergoing a consolidation and restructuring phase that signals market maturation. Abridge cut its workforce as part of an organization-wide realignment, though the company did not disclose the number of affected staff; it has raised more than $750 million in venture capital and works with more than 300 health systems [3l]. Heidi reduced its headcount by 18%, affecting approximately 108 staff, as it refocused investment on priority teams and market…
LeanTaaS Expands Hospital Operations Platform Into Ambient Intelligence
LeanTaaS acquired LookDeep Health to integrate computer vision and ambient intelligence into its iQueue hospital operations platform, planning to launch iQueue for Virtual Care with AI-powered patient-room monitoring for fall risks, patient movement, and other environmental signals [3k]. The company's software is used by nearly 200 health systems in more than 1,200 hospitals. LookDeep's deployments have reported more than a 70% reduction in fall rates and an 80% reduction in medication errors. T…
Siemens Healthineers Carves Out IVD Business as Olyrian Diagnostics
Siemens Healthineers initiated the carve-out process for its in vitro diagnostics business, which will become a standalone company under the name Olyrian Diagnostics [Source: https://www.siemens-healthineers.com/press (company announcement — may reflect promotional framing)]. The company also reported strong fourth-quarter results for fiscal year 2026, with strong order intake growth, comparable sales growth, and strong margin expansion. The IVD carve-out represents a significant strategic restr…
CVS Health Split Signals End of Vertical Integration Model; Conflict of Interest Questions Persist
CVS Health's announcement that it will split into two companies by the first half of 2028 — separating CVS Pharmacy from a healthcare solutions company retaining Aetna, Caremark, Oak Street Health, and Signify Health — was described by CEO David Joyner as positioning both companies to thrive regardless of the regulatory environment [3c]. However, industry observers noted that the PBM and insurance businesses remain together in the new CVS Health entity, and specialty pharmacy stays with the PBM,…
制度・規制動向
FDA Grants Accelerated Approval for Head and Neck Cancer; Cell and Gene Therapy Clarity Issued
The FDA granted accelerated approval to a new treatment for head and neck squamous cell carcinoma on November 5, adding to a series of oncology approvals this period [2]. According to MedCity News, the approval covers Johnson & Johnson's Rybrevant Faspro as a single-agent treatment for adults whose cancer has progressed on or after standard chemotherapy and immunotherapy, based on a 42% overall response rate in Phase 1b/2 results [5a]. On November 2, the FDA provided clarity to support cell and …
PMDA Publishes AI Regulatory Principles; Japan Signals Formal AI Governance Framework
Japan's PMDA posted new Basic Principles for the Use of AI in Regulatory Activities (Early Consideration) on November 2, marking the first formal articulation of how the agency intends to govern AI in its regulatory processes [4]. This development, combined with the PMDA's ongoing GLP-1 proper use alert and updated learning video content, signals that Japanese regulators are building a structured AI governance framework in parallel with the FDA and MHRA. The early consideration designation sugge…
CMS Finalizes 2027 Physician Fee Schedule and OPPS Rules With Significant Payment Cuts
CMS finalized the 2027 Medicare Physician Fee Schedule on November 4, including a roughly 2% reduction in baseline physician payment rates, with the conversion factor for non-APM participants dropping from $33.40 to $32.63 — steeper than the proposed 1.68% cut [3b]. The rule also finalizes a ban on third-party RPM vendors, though with a two-year delay to January 1, 2029. CMS also finalized the 2027 Hospital Outpatient Prospective Payment rule with a 2.3% reimbursement increase and a controversia…
MHRA Strengthens Patient Involvement and Clinical Trial Diversity Frameworks
The MHRA published its Patient and Public Involvement and Engagement Plan 2026-2030 on November 5, setting out an approach to broaden participation and clarify how patient experience informs regulatory decisions [10]. On November 3, the MHRA published findings from its Inclusion and Diversity Plan pilot for clinical trials, which ran for six months in 2025 with seven studies; findings indicated researchers found benefit in developing a plan at the point of study design, with a broader 12-month i…
Democratic Midterm Wave Reshapes Healthcare Policy Outlook; Bipartisan AI and Prior Auth Action Expected
Democrats flipped seven Senate seats and 21 House seats in the November 3 midterm elections, setting up comfortable majorities, according to Fierce Healthcare reporting [3a]. KFF Health News reported that the midterm wave sets a course for a Medicare for All fight, though analysts note passage is unlikely under a divided government with a Trump veto [6]. PricewaterhouseCoopers advised in a policy note that targeted bipartisan legislation is most likely to move, specifically citing cybersecurity,…
ソース活動
先週からの変化
CMS Finalizes 2027 PFS and OPPS Rules With Steeper-Than-Proposed Cuts
CMS finalized the 2027 Physician Fee Schedule with a 2.31% conversion factor reduction for non-APM participants and a 1.83% reduction for APM participants — both steeper than proposed — and finalized the 2027 OPPS rule with a 2.3% outpatient payment increase alongside a 340B drug reimbursement cut from ASP plus 6% to ASP minus 28%, reducing Original Medicare drug payments by $4.35 billion in year one [3b]. The RPM third-party vendor ban was finalized but delayed to January 1, 2029 [3r].
Democratic Midterm Blue Wave Reshapes Congressional Healthcare Agenda
Democrats flipped seven Senate seats and 21 House seats in the November 3 midterms, creating comfortable majorities and installing new committee chairs including Bernie Sanders at HELP and Ron Wyden at Finance [3a]. KFF Health News reported the wave sets a course for a Medicare for All fight, though analysts expect bipartisan action on AI, cybersecurity, and prior authorization to be more immediately achievable [6]. The new majority will also bring aggressive oversight of Medicare Advantage, pri…
CVS Health Announces Split Into Two Companies by 2028
CVS Health announced it will divide into two separate companies by the first half of 2028: CVS Pharmacy (retail pharmacies and Health100 technology) and a new CVS Health entity retaining Aetna, Caremark, Oak Street Health, and Signify Health [Source: https://www.fiercehealthcare.com/payers/cvs-reveals-plans-split-two-companies (company announcement — may reflect promotional framing)]. Industry observers noted the PBM and insurance businesses remain together, leaving the core conflict of interest…
PMDA Publishes AI Regulatory Principles; FDA Grants Head and Neck Cancer Accelerated Approval
Japan's PMDA posted Basic Principles for the Use of AI in Regulatory Activities (Early Consideration) on November 2, the first formal articulation of AI governance for Japanese regulatory processes [4]. The FDA granted accelerated approval to a new treatment for head and neck squamous cell carcinoma on November 5 [2a], confirmed by MedCity News as J&J's Rybrevant Faspro based on a 42% overall response rate [5a].
Measles Outbreak Escalates With Multiple Deaths; U.S. Surpasses 4,852 Cases
The U.S. measles outbreak reached 4,852 confirmed cases as of October 29, with Wisconsin reporting its first infant measles-associated death since 1990 on November 5 and New York reporting its first child death in 30 years on November 3 [3h]. Pennsylvania has confirmed five measles-associated deaths. The CDC's death count remains lower than state-reported figures due to an ongoing effort to develop a standardized case definition. The outbreak is occurring against a backdrop of declining vaccinat…
ウォッチリスト — 今後の締切
FDA and Focused Ultrasound Foundation Co-sponsored Public Workshop: Research Roundtable on Transcranial Ultrasound for Neurological and Psychiatric Applications
ソース: FDA NewsFDA Public Virtual Only Workshop: Maintenance Treatment for Ovarian Cancer — Weighing Benefit and Toxicity in an Evolving Landscape
ソース: FDA News示唆・見るべき論点（9件）
- 1.The CMS RPM third-party vendor ban's two-year delay to January 1, 2029 [3b] gives digital health companies a window to restructure their business models, but the policy direction is clear. Companies relying on third-party RPM billing arrangements should use the reprieve to develop direct employment or alternative contracting structures rather than assuming the ban will be reversed.
- 2.The 340B reimbursement cut from ASP plus 6% to ASP minus 28% [3r] will disproportionately affect safety-net hospitals that depend on 340B drug savings to cross-subsidize care for low-income patients. Health systems with significant 340B revenue should model the first-year $4.35 billion reduction against their specific drug mix and patient population to quantify exposure before January 2027.
- 3.Athenahealth's decision to build athenaPatient MCP on the Model Context Protocol rather than a proprietary integration [3d] is a strategic bet that MCP becomes the industry standard for AI-health data interoperability. EHR vendors and health IT companies should evaluate whether to adopt MCP as a standard or develop competing interoperability frameworks before the market converges.
- 4.The Bessemer Venture Partners Healthcare AI ROI Scorecard cited in MedCity News found that only 46% of healthcare executives trust AI-generated tools to support clinical decision-making and 77% override AI suggestions more than half the time [5c]. This trust gap is the primary barrier to AI ROI realization in healthcare and should be the focus of AI vendor go-to-market strategies.
- 5.The Democratic midterm wave's installation of Ron Wyden as Finance Committee chair — who recently endorsed Medicare for All and has led oversight of insurer prior authorization practices — signals that Medicare Advantage plans should prepare for aggressive congressional scrutiny of their prior authorization algorithms, post-acute care denial rates, and risk adjustment practices [3a].
- 6.Hims & Hers' transition from compounded GLP-1s to branded partnerships with both Novo Nordisk and Eli Lilly [3g] demonstrates that the telehealth-to-pharma distribution model is viable for branded drugs at self-pay prices. Other telehealth platforms should evaluate similar direct-to-consumer branded drug distribution agreements as the compounded GLP-1 market closes.
- 7.The PMDA's publication of Basic Principles for the Use of AI in Regulatory Activities [4] as an early consideration document means companies seeking AI-enabled medical device approval in Japan should engage with PMDA now to shape the final framework rather than waiting for binding guidance. Early engagement with regulators during framework development has historically produced more favorable outcomes for industry.
- 8.The measles outbreak's death toll and the CDC's lagging official count relative to state-reported figures [3h] reflect a breakdown in federal-state public health data coordination that has implications beyond measles. Health systems in affected states should review their own vaccination outreach programs and consider proactive community immunization campaigns independent of federal messaging.
- 9.The AMA's House of Delegates Interim Meeting this week, where the CEO called on physicians to lead medicine through rapid change [11], signals that organized medicine is positioning itself as a governance voice in AI deployment decisions. Health systems deploying AI tools should engage physician leadership in governance structures proactively to avoid the AMA framework being used as a basis for physician resistance to AI adoption.
信頼度サマリー
今週引用したソース 22 件あなたが選んだ 30 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
WHO published the Global report on neglected tropical diseases 2026 mid-term evaluation (Nov 4), a Digital adaptation kits implementation facilitation guide (Nov 4), updated foodborne disease burden estimates for 2000-2021 (Nov 4), and a report on primary health care for migrants and refugees (Nov 5).
FDA granted accelerated approval to a new treatment for head and neck squamous cell carcinoma (Nov 5), provided clarity to support cell and gene therapy development and quality (Nov 2), and has upcoming events including a transcranial ultrasound workshop (Nov 10) and ovarian cancer maintenance treatment workshop (Nov 12).
Reporting on Democratic midterm blue wave healthcare implications, CMS 2027 PFS and OPPS final rules, CVS Health split, athenahealth-Claude MCP integration, Hinge Health Q3 results, Hims & Hers-Eli Lilly GLP-1 deal, Mayo Clinic Platform AI CDS launch, LeanTaaS-LookDeep acquisition, Abridge and Heidi layoffs, measles outbreak deaths, Samaritan-MultiCare merger close, Midstream Health $20M Series A, Humana Q3 earnings, Oscar Health Q3 earnings, Clover Health Q3 earnings, Omada Health Q3 earnings, and court blocking CMS ACA broker moratorium.
PMDA posted Basic Principles for the Use of AI in Regulatory Activities (Early Consideration) on November 2, updated PMDA-ATC Learning Videos, and maintained the GLP-1 proper use alert from October 30.
Reporting on J&J Rybrevant Faspro FDA approval for head and neck cancer, CVS Health split conflict of interest analysis, Bessemer Ventures Healthcare AI ROI Scorecard findings, HHS HTI-5 health IT certification rollback shifting oversight to health systems, Medicare AI prior authorization WISeR model problems, Inovio Voceryq FDA approval for recurrent respiratory papillomatosis, Servier muscular dystrophy drug pivotal trial failure, Mount Sinai NIH $4M grant for AI kidney injury prediction model, and Integris Health joining Risant Health.
KFF Health News reporting on Democratic midterm wave and Medicare for All fight (Nov 6), healthcare cuts fueling Democrats' election blowout (Nov 6), midterm voters split on abortion and trans healthcare ballot questions (Nov 5), Democrats' election rout poised to dramatically reorder federal health policy (Nov 4), and Trump administration delays to rural health awards (Nov 5).
NIH published research on integrated health service delivery through medical mobile units reducing deaths among individuals at risk for HIV who inject drugs (Nov 4), and research on two forever chemicals associated with higher risk of aggressive breast cancer (Nov 5).
Cochrane appointed its first Chief Community Officer on November 5. Background: Cochrane review from October 28 found ergonomic interventions show no meaningful benefit for work-related arm, neck or shoulder complaints.
ECDC published news on EU Reference Laboratories for Public Health on European Laboratory Day (Nov 5), noting strong laboratory capacity as the backbone of Europe's preparedness against communicable disease threats.
MHRA published Patient and Public Involvement and Engagement Plan 2026-2030 (Nov 5), opened Digital Mental Health Technologies Phase 1 evaluation survey (Nov 5), published Inclusion and Diversity Plan pilot findings for clinical trials (Nov 3), and issued guidance on non-OECD MAD non-clinical data for clinical trial authorisation applications (Nov 4).
AMA CEO called on physicians to lead medicine through rapid change at the House of Delegates Interim Meeting (Nov 6); AMA president called on physicians to reimagine the future of medicine (Nov 6); AMA applauded CMS adoption of modernized maternity care codes (Nov 5).
Boston Scientific reported that the SIMPLAAFY study of the WATCHMAN FLX Pro Left Atrial Appendage Closure Device met primary endpoints, with both post-implant monotherapies achieving non-inferiority compared to dual anti-platelet therapy (Nov 2).
Siemens Healthineers initiated the carve-out of its in vitro diagnostics business as a standalone company under the name Olyrian Diagnostics (Nov 5), and reported strong fourth-quarter fiscal year 2026 results with strong order intake growth and margin expansion.
NICE reported that prescribing of NICE-recommended tablets for endometriosis and fibroids has more than tripled in a year across England; published news on new AI tools to help spot prostate cancer more accurately; and recommended Enhertu for HER2-low advanced breast cancer.
BD reported Q4 revenue of $5.3 billion, up 5.4% as reported, and full-year fiscal 2026 revenue of $19.5 billion, up 4.9% as reported (Nov 5). BD Board increased dividend for the 55th consecutive year and authorized 10 million additional share repurchases.
Epic reported that its Art AI for clinicians helps nurses sort, prioritize, and draft replies to patient messages (Nov 4); launched Reach Out and Read configuration for child literacy documentation (Nov 6).
Medtronic and the Michael J. Fox Foundation partnered to expand awareness of Deep Brain Stimulation for Parkinson's disease (Nov 4); Medtronic's Symplicity blood pressure procedure showed significant blood pressure drops in the SPYRAL AFFIRM real-world study at TCT26, with nearly nine out of 10 patients experiencing clinical benefit at six months (Nov 3).
Philips delivered strong order intake growth, comparable sales growth, and strong margin expansion in Q3 2026 with 2026 outlook reiterated (Nov 3); launched HyperVue Integrated System in the U.S. for advanced coronary imaging and physiology in the cathlab (Nov 2).
CVS Health reported Q3 2026 results with $2.2 billion in profit and $108.4 billion in revenue, and raised full-year 2026 guidance (Nov 4). CVS announced plans to split into two companies by the first half of 2028.
UnitedHealthcare announced it is making it easier and quicker for children to get care by eliminating prior authorization requirements on 2,000 pediatric care services (Nov 2). UnitedHealth Group Board authorized payment of quarterly dividend (Nov 4).
MHLW issued a security alert on unauthorized access and information leakage (Nov 6), updated influenza and COVID-19 surveillance data (Nov 6), and published the 2026 cause of death investigation white paper (Nov 6). November is designated as antimicrobial resistance (AMR) countermeasures promotion month.
Intuitive Surgical published articles on da Vinci OS5 v2.0 introduction, da Vinci cardiac surgery entering a new era, and hospital infrastructure with da Vinci 5 during the week. No new press releases were issued this week.
Healthcare AI & Digital Healthを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める